This article was originally published in The Gray Sheet
Duke University analysis places annual U.S. costs at up to $162 mil. Pooling results from seven different angioplasty trials including a total of 5,143 patients, researchers concluded that one of every 12 patients "may not need stents because their vessels are very unlikely to renarrow after balloon angioplasty." Candidates are likely to include males, patients with short atherosclerotic lesions, and lesions not at the top of the left anterior descending artery
You may also be interested in...
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.